030 ImmunoScape: Safe and Efficacious Drugs for Solid Tumors

One North Stories

This is One North Stories, an A*START CENTRAL Podcast

Choon joins to share about ImmunoScape, a Singapore biotech start-up building a TCR discovery platform and therapeutics pipeline with a focus on TCRs to fight solid tumors. Choon started his career in the Singapore Armed Forces. He pursued his MBA at the University of Michigan after which he joined the pharmaceuticals industry, first in the USA and then back in Singapore and across Asia. He joined A*STAR to lead the Pharmaceuticals and Biologics cluster. After some time, the calling of industry came again, and he started looking for technologies and partners to spin out a company. He met Alessandra Nardin, Michael Fehlings and Evan Newell.

ImmunoScape was formed in 2017, originally doing immune profiling projects for pharmaceutical companies. Realizing their strengths in TCR based therapeutics discovery, they changed their approach, building up a TCR discovery platform with a tight feedback loop between wet chemistry and machine learning. Spanning across Singapore and the USA, Choon is quite pragmatic about steering ImmunoScape, their IP assets, technology and partnerships. The ultimate goal is to bring safe and efficacious drugs to patients as quickly as possible.

Learn more about Choon, ImmunoScape and the amazing work they are doing:

Choon (LinkedIn)

Immunoscape (LinkedIn)

Immunoscape (Website)

Thank you for listening. If you like what you’ve heard, please share with a friend. After that, please subscribe and review us wherever you get your podcasts.

Check out A*START CENTRAL (Website, LinkedIn)

If you have future episode ideas, segments ideas or want to partner with us on this exciting journey, please get in touch: [e-mail]